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Erlotinib hydrochloride is an Anti neoplastic agent, which 
is used for lung and various other types of cancer. Erlotinib 
hydrochloride targets the epidermal growth factor 
receptors. Chemically Erlotinib Hydrochloride is N-(3-
ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4 
amine1. Erlotinib Hydrochloride acts by inhibiting the 
intracellular phosphorylation of tyrokinase associated with 
the epidermal growth factor receptor (EGFR). EGFR is 
expressed on the cell surface of normal cells and cancer 
cells. Erlotinib Hydrochloride is available as an oral agent 
that blocks transduction of propagation signals mediated 
by the EGRF. It also has the potential to cause drug-drug 
interaction when given in conjugation with agents that are 
classified as CYPA4 inducers. 
 
 
Figure 1: Structure of Erlotinib Hydrochloride 
Literatura review suggest few HPLC 2-4,HPTLC5, 
spectroscopic 6, Stability indicating HPLC 7 determinations 
were performed. After doing in depth study in the present 
research work, it was found that the present research work 
is having various advantages over the previous work. The 
advantages include less retention times of the component, 
with good resolution and with more number of theoretical 
plates. The % RSD of robustness was found to be less. The 
results obtained from the validation suggest that the 
method was found to be precise, accurate, linear and robust 
enough and the method was found to be economical. The 
aim of the present study is to develop a simple, precise, 
accurate, sensitive HPLC method for the determination of 
Erlotinib hydrochloride in bulk and tablet dosage form. 
The method was validated in compliance with ICH 
guidelines (International Conference on Harmonization, 
Geneva. 1996)8. 
EXPERIMENTAL WORK: 
Chemicals and reagents 
HPLC grade acetonotrile, methanol, from 
Rankem pvt Ltd. Ammonium acetate, acetic acid of 
analytical grade were used. Millipore grade water was 
used. The reference standard samples of Erlotinib 
hydrochloride was provided was provided by LAURUS 
LABS LTD, Hyderabad. Tarceva tablet dosage form 
containing 100 mg of Erlotinib Hydrochloride was 
purchased from the local market. 
Instrumentation and analytical conditions 
The analysis was carried out by using LC-2010 
HCT Shimadzu, equipped with auto sampler and UV 
detector with Empower-2 software. Double beam UV- 
Visible spectrophotometer (Perkin Elmer), digital balance 
(metler tolado), vacuum pump (Gelman science), pH meter 
(poloman) 
Chromatographic conditions 
A Zorbax XDB C18 column (150 X 4.6 mm I.D, 
5 µ) was used for separation. The mobile phase consists of 
Acetonitrile and 0.02M ammonium acetate, adjusted to pH 
3.3 with acetic acid. Acetonitrile and water (50:50) was 
used as diluents. Flow rate was delivered at 1.0 mL/min 
with detection wavelength at 247 nm. A 20 µL was 
injected to the chromatographic system with ambient 
temperature. 
Preparation of Standard stock solution: 
An accurately weighed quantity of 100 mg of 
Erlotinib hydrochloride into 100mL volumetric flask. 
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Dissolve in about 30 mL of diluent and sonicate for about 
5 mins until all the contents were dissolved, then the 
volume was made upto the mark with diluent. The 
concentration of Erlotinib hydrochloride was found to be 
1000 µg/mL. 
Preparation of sample solution: 
Weigh accurately about 20 tablets and powdered. An 
equivalent amount of 100 mg of Erlotinib hydrochloride 
was taken into 100 mL volumetric flask. Add about 30 mL 
of diluents and sonicate for 5 mins until all the contents 
were dissolved. Make upto the mark with diluents. Filter 
the contents by using 0.45 µ membrane under vacuum. 
The concentration of Erlotinib hydrochloride was found to 
be 1000µg/mL. 
Validation procedure 
The objective of the method validation is to 
demonstrate whether the method was suited for the 
intended purpose. The method was validated as per the 
ICH guidelines. The method was validated for linearity, 
precision (repeatability, intermediate precision), accuracy, 
specificity, robustness, ruggedness, limit of detection, limit 
of quantification. A calibration graph was constructed by 
taking six different concentrations, ranging from 50 – 150 
µg/mL. The peak area was calculated and calibration curve 
was constructed by taking peak area and concentration on 
both the axis. The linearity was evaluated by linear 
regression analysis. The precision studies were 
demonstrated by two parameters inter day and intraday 
precision. Intraday precision was performed by injecting 
six replicated injections to the chromatographic system on 
the same day and calculated the %RSD. The inter day 
precision was performed by injecting six replicated 
injections at two consecutive days. From the peak area of 
the chromatograms, the %RSD was calculated. The 
accuracy was determined by adding a known amount of 
the standard to the sample, and the percentage recovery 
was estimated. The robustness was determined by 
incorporating deliberate changes into the method 
conditions like the change in flow rate, pH, and gradient.  
Ruggedness was performed by carrying out the proposed 
method with two different analysts. 
RESULTS AND DISCUSSION 
Selection of wavelength 
UV spectrum was obtained by preparing a 
solution by taking diluents and scanned between 200 to 
400 nm. Erlotinib Hydrochloride shows λmax at 247 nm. 
So it is selected as a detection wavelength.
  
 
Figure 2: UV – Spectrum of Erlotinib Hydrochloride 
Development and optimization of the HPLC method: 
 For getting an optimized chromatographic 
condition, a Zorbax XDB C18 column (150 X 4.6 mm I.D, 
5µ) was used as stationary phase. The mobile phase 
consists of Acetonitrile and 0.02M ammonium acetate, 
adjusted to pH 3.3 with acetic acid. Acetonitrile and water 
(50:50) was used as diluents. Flow rate was delivered at 
1.0 mL/min with detection wavelength at 247 nm. The run 










Linearity studies were performed by taking serial dilutions 
of 0.5, 0.75, 1.0, 1.2, 1.5 mL from the stock solution into 
various 10 mL flasks and made up to the volume with 
diluent. These concentrations were injected into the 
chromatographic system and record the response. Erlotinib 
hydrochloride shows linearity in the range of 50 – 150 
µg/mL. The calibration graph was plotted by taking peak 
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area on the Y axis and concentration of standard solution 
on X axis. The degree of linearity was determined by 
calculating the correlation coefficient. The slope, intercept 
and correlation coefficient of Erlotinib hydrochloride was 
found to be 12503, 56891 and 0.999 respectively. 
 
Figure 4: Calibration curve of Erlotinib Hydrochloride 
Table 1: Linearity Data 
 
Precision  
Six individual preparations containing 100mg/100 mL of 
stock solution were prepared from that, Pipette out 1.0 mL 
from each stock solution into a six 10 mL volumetric flask, 
and made upto the mark with diluent, mix well and the 
solutions contain 100µg/mL of Erlotinib hydrochloride.
 
Table 2: Precision Data 
S.NO Concentration (µg/mL) Area of Erlotinib HCl Stastical Analysis (n=6) 
1. 100 12530617 
Mean   = 12390441 
SD     =76641.8 
%RSD = 0.61 
 
2. 100 12419412 
3. 100 12305124 
4. 100 12383824 
5. 100 12304657 
6. 100 12399014 
 
Table 3: Intraday Precision Data 
S.NO Concentration (µg/mL) Area of Erlotinib HCl Stastical Analysis (n=6) 
1. 100 12340712 
Mean   = 12375323 
SD     =37668.006 
%RSD = 0.30 
 
2. 100 12418417 
3. 100 12419025 
4. 100 12329012 
5. 100 12346057 
6. 100 12398715 
 
Table 4: Interday Precision 
S.NO Concentration (µg/mL) Area of Erlotinib HCl Stastical Analysis 
1. 100 12430617 
Mean   = 12353775 
SD     =41375.508 
%RSD = 0.33 
 
2. 100 12319412 
3. 100 12305124 
4. 100 12343824 
5. 100 12344657 
6. 100 12379014 
 
Accuracy: 
              Accuracy is usually reported as percent recovery 
by assay, using the proposed analytical procedure, of 
known amount of analyte added to the sample.  
                To determine the accuracy of a method, stability 
of a method recovery studies were performed by 
comparing the known quantity of standard with that of the 
sample. The percentage recovery can be calculated from 
the respective chromatograms. From the results we can 
determine that the method was accurate.  
 
 


















Linearity of Erlotinib HCl
S.No Concentration(µg/mL) Peak Area 
1. 50 6173871 
2. 75 9257219 
3. 100 12441322 
4. 120 15184469 
5. 150 18550680 
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Table 5: Accuracy Data 









1. 80 80 22511646 79.45 99.16 ±0.277 
2. 100 100 24995758 99.35 99.45 ±0.163 
3. 120 120 27512966 119.45 99.6 ±0.340 
 
Limit of Quantification: 
                   The limit of quantification (LOQ) is defined as 
the lower concentration of an analyte in a sample that can 
be determined with acceptable precision and accuracy 
under the stated operational conditions of the method.  
                Various determinations were performed by 
taking different concentrations in their decreasing order 
from stock solution such as 10µg/mL, 1µg/mL, 0.5 µg/mL, 
and 0.04µg/mL. The LOQ value of Erlotinib hydrochloride 
was found to be 0.04µg/mL according to the s/n value. The 
s/n value of LOQ was found to be 11 
Limit of Detection (LOD): 
              The limit of detection (LOD) is defined as the 
lowest concentration of an analyte in a sample that can be 
detected, not quantified. The limit of detection can be 
performed by injecting the lowest amount of the analyte 
and observed for the accurate, precise and acceptable 
method development. 
The limit of detection for Erlotinib hydrochloride was 
found to be 0.01 µg/mL, according to the s/n value. The 
s/n value was found to be 3.0 
ROBUSTNESS 
                   The robustness of an analytical procedure is a 
measure of its capacity to remain unaffected by small but 
deliberate variations in the analytical procedure 
parameters. For determining the robustness of the method 
which was developed, the conditions which were used in 
the method development were changed. The method must 
be robust enough so that it can remain unaffected by the 
deliberate change in the method conditions. 
i) Effect of flow rate 
       Robustness of a method can be determined by 
changing the flow rate conditions. The initial flow rate was 
set at 1.0 mL per min. The flow rate was altered to 0.8 
mL/min, and 1.2 mL/ min. Observed for any changes. 
ii)  Effect of pH: 
               Robustness of a method can be determined by 
changing the pH of the mobile phase. The optimized pH 
condition was 3.3. The pH was altered to 3.2 and 3.4 and 
observed for any changes. 
RUGGEDNESS 
                       Ruggedness as the degree of reproducibility 
of test results obtained by the analysis of the same samples 
under a variety of normal test condition such as different 
labs, different analyst. Ruggedness is a measure of 
reproducibility of test results under normal expected 
operational conditions from laboratory and from analyst to 
analyst. The ruggedness was performed by two different 
analysts, and observed the analyst to analyst variation. 
Table 6: Ruggedness Data 
 
Analyst 
Peak area of Erlotinib HCl 
Analyst 1 12530617 








Inject 20 µl of standard and sample solution into the 
chromatographic system and measure the area of Erlotinib 
hydrochloride and calculate the percentage assay by using 
the following formula. 
                        

















AT = Peak area of test preparation 
AS = peak area of standard preparation 
WS = weight of working standard in mg 
WT = weight of sample taken in mg 
DS = dilution of standard solution 
DT = dilution of test solution 
P = percentage purity of working standard. 
Table 8: Assay Data 
 
CONCLUSION 
A precise RP – HPLC method was developed for 
the determination of Erlotinib hydrochloride. The shorter 
run time elutes Erlotinib hydrochloride with good 
resolution, and symmetry. The method was validated as 
per the ICH guidelines and the method was found to be 















%Amount   
    Found 
Erlotinib HCl 100 100.76 100.76 
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